SEARCH

SEARCH BY CITATION

References

  • 1
    Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 168595.
  • 2
    Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 11526.
  • 3
    Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 41724.
  • 4
    Meier CR, Jick SS, Derby LE, Vasilakis C, Jick H. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet 1998; 351: 146771.
  • 5
    Vallance P, Collier J, Bhagat K. Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link? Lancet 1997; 349: 13912.
  • 6
    Weyrich AS, Lindemann S, Zimmerman GA. The evolving role of platelets in inflammation. J Thromb Haemost 2003; 1: 1897905.
  • 7
    Sarma J, Laan CA, Alam S, Jha A, Fox KAA, Dransfield I. Increased platelet binding to circulating monocytes in acute coronary syndromes. Circulation 2002; 105: 216671.
  • 8
    Collaborative overview of randomised trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ 1994; 308: 81106.
  • 9
    Sandercock P, Gubitz G, Foley P, Counsell C. Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2003; Issue 2: CD000029.
  • 10
    Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest 2001; 119 (Suppl. 1): 39S63S.
  • 11
    Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000; 343: 113947.
  • 12
    Reinhart WH. Fibrinogen–marker or mediator of vascular disease? Vasc Med 2003; 8: 2116.
  • 13
    Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schror K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999; 353: 900.
  • 14
    Myocardial infarction redefined–a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. Eur Heart J 2000; 21: 150213.
  • 15
    Ozaki Y, Satoh K, Yatomi Y, Yamamoto T, Shirasawa Y, Kume S. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994; 218: 28494.
  • 16
    Satoh K, Ozaki Y, Qi R, Yang L, Asazuma N, Yatomi Y, Kume S. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based upon light scattering. Thromb Res 1996; 81: 51523.
  • 17
    Eto K, Takeshita S, Ochiai M, Ozaki Y, Sato T, Isshiki T. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser light scattering to assess platelet aggregability. Cardiovasc Res 1998; 40: 2239.
  • 18
    Sakamoto T, Ogawa H, Kawano H, Hirai N, Miyamoto S, Takazoe K, Soejima H, Kugiyama K, Yoshimura M, Yasue H. Rapid change of platelet aggregability in acute hyperglycemia. Detection by a novel laser-light scattering method. Thromb Haemost 2000; 83: 4759.
  • 19
    Miyamoto S, Ogawa H, Soejima H, Takazoe K, Sakamoto T, Yoshimura M, Kugiyama K, Yasue H. Formation of platelet aggregates after attacks of coronary spastic angina pectoris. Am J Cardiol 2000; 85: 4947, A10.
  • 20
    Miyamoto S, Kawano H, Sakamoto T, Soejima H, Kajiwara I, Shimomura H, Kojima S, Hokamaki J, Sugiyama S, Hirai N, Yoshimura M, Ozaki Y, Ogawa H. Formation of platelet microaggregates correlates with adverse clinical outcome in patients with coronary artery disease. Thromb Haemost 2003; 89: 6816.
  • 21
    Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer – PFA-100. Semin Thromb Hemost 1995; 21 (Suppl. 2): 10612.
  • 22
    Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24: 195202.
  • 23
    Crowe B, Abbas S, Meany B, De Haan J, Cahill MR. Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina. Semin Thromb Hemost 2005; 31: 4205.
  • 24
    Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 9615.
  • 25
    Borna C, Lazarowski E, Van Heusden C, Ohlin H, Erlinge D. Resistance to aspirin is increased by ST-elevation myocardial infarction and correlates with adenosine diphosphate levels. Thromb J 2005; 3: 10.
  • 26
    Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol 2004; 24: 19807.
  • 27
    Frelinger AL Jr, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation 2006; 113: 288896.
  • 28
    Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 2006; 47: 21222.